Compare Amylx Pharmaceuticals Inc (AMLX) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $17.3 (market cap $1.98B), while Invesco S&P 500 Low Volatility ETF trades at $76.14. Which is the better fit depends on your goals.
| AMLX | SPLV | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | — |
52-Week High | $18.70 | $77.45 |
52-Week Low | $7.64 | $70.30 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
SPLV trades at $75.84, up 0.45% today, with a bullish technical signal from moving averages. The ETF, tracking the S&P 500 Low Volatility Index, holds 100 low-volatility stocks and has $6.93 billion in assets. Recent news highlights its role in diversification amid market volatility, with a dividend scheduled for June 2026.
Outlook remains stable given its low-volatility mandate, offering defensive exposure during uncertain markets. Risks include underperformance in strong bull markets and sensitivity to interest rate changes. The ETF appeals to risk-averse investors seeking steady returns with reduced downside volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
